Cargando…

A phase II study of cisplatin plus vinorelbine combined with atezolizumab as adjuvant therapy for completely resected non-small-cell lung cancer with EGFR mutation (West Japan Oncology Group 11719L/ADJUST study)

BACKGROUND: Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) is a standard treatment in EGFR-mutated advanced non-small-cell lung cancer (NSCLC); however, previous data have suggested that EGFR-TKI has limited potential as adjuvant therapy. On the contrary, based on subset ana...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shibaki, Ryota, Akamatsu, Hiroaki, Kato, Terufumi, Nishino, Kazumi, Okada, Morihito, Mitsudomi, Tetsuya, Wakuda, Kazushige, Yoshimura, Kenichi, Yamamoto, Nobuyuki, Nakagawa, Kazuhiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Immunotherapy for lung cancer: progress, opportunities and challenges
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7841658/ https://www.ncbi.nlm.nih.gov/pubmed/33613698 http://dx.doi.org/10.1177/1758835920987647

Ejemplares similares

A phase II study of atezolizumab for pretreated advanced/recurrent non-small cell lung cancer with idiopathic interstitial pneumonias: rationale and design for the TORG1936/AMBITIOUS study
por: Ikeda, Satoshi, et al.
Publicado: (2020)

The evolving immuno-oncology landscape in advanced lung cancer: first-line treatment of non-small cell lung cancer
por: Low, Jia Li, et al.
Publicado: (2019)

Rationale and design of a phase II trial of durvalumab treatment in patients with NSCLC ineligible for stage III chemoradiotherapy following radiation monotherapy (SPIRAL-RT study)
por: Yamada, Tadaaki, et al.
Publicado: (2020)

KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC
por: Cinausero, Marika, et al.
Publicado: (2019)

Chemo-immunotherapy as first-line treatment for small-cell lung cancer
por: Farid, Saira, et al.
Publicado: (2020)

Effect of immunotherapy on overall survival in limited-stage small cell lung carcinoma: a national cancer database analysis
por: Bilani, Nadeem, et al.
Publicado: (2021)

TGFBR2 mutation predicts resistance to immune checkpoint inhibitors in patients with non-small cell lung cancer
por: Li, Teng, et al.
Publicado: (2021)

Is there any room for PD-1 inhibitors in combination with platinum-based chemotherapy as frontline treatment of extensive-stage small cell lung cancer? A systematic review and meta-analysis with indirect comparisons among subgroups and landmark survival analyses
por: Gristina, Valerio, et al.
Publicado: (2021)

Harnessing the epigenome to boost immunotherapy response in non-small cell lung cancer patients
por: Gkountakos, Anastasios, et al.
Publicado: (2021)

Validation of Patras Immunotherapy Score model for prediction and prognosis of patients with advanced NSCLC treated with nivolumab or pembrolizumab: results from a European multicentre study
por: Dimitrakopoulos, Foteinos-Ioannis, et al.
Publicado: (2022)

Immune checkpoint inhibitors plus chemotherapy in patients with locally advanced or metastatic pulmonary sarcomatoid carcinoma: a multicentric real-world study
por: Zhou, Fei, et al.
Publicado: (2022)

Treatment strategies based on different oligoprogressive patterns after immunotherapy failure in metastatic NSCLC
por: Xuzhang, Wendi, et al.
Publicado: (2023)

Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC)
por: Moya-Horno, Irene, et al.
Publicado: (2018)

The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer
por: Qu, Jingjing, et al.
Publicado: (2021)

Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study)
por: Seto, Takashi, et al.
Publicado: (2022)

Distribution and characterization of microplastics in marine sediments from the Montenegrin coast
por: Bošković, Neda, et al.
Publicado: (2022)

The impact of COVID-19 on tuberculosis: challenges and opportunities
por: Kant, Surya, et al.
Publicado: (2021)

Bronchial brushing Xpert improves the diagnostic efficiency of sputum Xpert in patients with pulmonary tuberculosis
por: He, Yu, et al.
Publicado: (2021)

The role of bronchoscopy in the diagnosis and management of pediatric pulmonary tuberculosis
por: Goussard, Pierre, et al.
Publicado: (2021)

Development of a nomogram for predicting treatment default under facility-based directly observed therapy short-course in a region with a high tuberculosis burden
por: Wang, Saibin
Publicado: (2021)

Addressing TB-related mortality in adults living with HIV: a review of the challenges and potential solutions
por: Sullivan, Amanda, et al.
Publicado: (2022)

Real‐world efficacy of atezolizumab in non‐small cell lung cancer: A multicenter cohort study focused on performance status and retreatment after failure of anti‐PD‐1 antibody
por: Furuya, Naoki, et al.
Publicado: (2021)

Epistemic modesty, ostentatiousness and the uncertainties of epigenetics: on the knowledge machinery of (social) science
por: Pickersgill, Martyn
Publicado: (2016)

Living well in the Neuropolis
por: Fitzgerald, Des, et al.
Publicado: (2016)

Early tumor shrinkage identifies long-term disease control and survival in patients with lung cancer treated with atezolizumab
por: Hopkins, Ashley M, et al.
Publicado: (2020)

Diabetic Retinopathy: Battling the Global Epidemic
por: Das, Arup
Publicado: (2016)

Report From the NEI/FDA Diabetic Retinopathy Clinical Trial Design and Endpoints Workshop
por: Nair, Prashant, et al.
Publicado: (2016)

Report From the NEI/FDA Endpoints Workshop on Age-Related Macular Degeneration and Inherited Retinal Diseases
por: Csaky, Karl, et al.
Publicado: (2018)

Opportunities from the Center for Perioperative Education
Publicado: (2006)

Opportunities from the Center for Perioperative Education
Publicado: (2006)

Opportunities from the Center for Perioperative Education
Publicado: (2006)

Report From the National Eye Institute Workshop on Neuro-Ophthalmic Disease Clinical Trial Endpoints: Optic Neuropathies
por: Levin, Leonard A., et al.
Publicado: (2021)

Report From the 2022 Mary Tyler Moore Vision Initiative Diabetic Retinal Disease Clinical Endpoints Workshop
por: Levine, S. Robert, et al.
Publicado: (2023)

A Randomized Phase II Study Comparing Nivolumab with Carboplatin–Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L)
por: Hayashi, Hidetoshi, et al.
Publicado: (2022)

A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer
por: Fong, Lawrence, et al.
Publicado: (2021)

Women and ARV-based prevention: opportunities and challenges
por: Geary, Cynthia W, et al.
Publicado: (2014)

Learning from the private sector: towards a keener understanding of the end-user for microbicide introduction planning
por: Lin, Amy H, et al.
Publicado: (2014)

Comparing patterns of sexual risk among adolescent and young women in a mixed-method study in Tanzania: implications for adolescent participation in HIV prevention trials
por: Tolley, Elizabeth E, et al.
Publicado: (2014)

Communicating about microbicides with women in mind: tailoring messages for specific audiences
por: Sidibe, Sekou, et al.
Publicado: (2014)

Perspectives on use of oral and vaginal antiretrovirals for HIV prevention: the VOICE-C qualitative study in Johannesburg, South Africa
por: van der Straten, Ariane, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_0m49qddl9kai63dk4m6v2odd9l